Accolade Inc (ACCD)

$7.02 -0.01 (-0.14%)
Market Cap 575.59M
Revenue (ttm) 414.29M
Net Income (ttm) -99.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.09%
Debt to Equity Ratio 0.67
Volume 4,585,600
Avg Vol 1,421,620
Day's Range N/A - N/A
Shares Out 81.99M
Stochastic %K 80%
Beta 2.10
Analysts Sell
Price Target $6.54

Latest News on ACCD

Digital health startup Transcarent takes Accolade private in $621 million deal

Apr 8, 2025, 9:55 AM EDT - 11 days ago

Digital health startup Transcarent takes Accolade private in $621 million deal

Transcarent Completes Merger With Accolade

Apr 8, 2025, 9:22 AM EDT - 11 days ago

Transcarent Completes Merger With Accolade

Accolade Stockholders Approve Merger Between Accolade and Transcarent

Mar 27, 2025, 4:05 PM EDT - 23 days ago

Accolade Stockholders Approve Merger Between Accolade and Transcarent

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Mar 6, 2025, 9:00 AM EST - 6 weeks ago

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

Feb 24, 2025, 5:20 PM EST - 7 weeks ago

Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering

Feb 4, 2025, 9:00 AM EST - 2 months ago

Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade

Jan 10, 2025, 8:24 PM EST - 3 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD

Jan 8, 2025, 5:48 PM EST - 3 months ago

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD

Why Is Accolade Stock Trading Over 100% On Tuesday?

Jan 8, 2025, 1:33 PM EST - 3 months ago

Why Is Accolade Stock Trading Over 100% On Tuesday?

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade

Jan 8, 2025, 11:07 AM EST - 3 months ago

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade

Transcarent To Acquire Accolade

Jan 8, 2025, 8:30 AM EST - 3 months ago

Transcarent To Acquire Accolade

Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Dec 16, 2024, 8:00 AM EST - 4 months ago

Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Accolade: A GARP Stock Trading Well Under 1X Revenues

Dec 5, 2024, 5:05 AM EST - 4 months ago

Accolade: A GARP Stock Trading Well Under 1X Revenues

Accolade To Present at Upcoming Investor Conferences

Nov 13, 2024, 8:00 AM EST - 5 months ago

Accolade To Present at Upcoming Investor Conferences

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

Oct 31, 2024, 9:03 AM EDT - 6 months ago

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Oct 15, 2024, 9:00 AM EDT - 6 months ago

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Oct 8, 2024, 10:27 AM EDT - 6 months ago

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30

Oct 8, 2024, 8:31 AM EDT - 6 months ago

Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30

Accolade Announces Results for Fiscal Second Quarter 2025

Oct 8, 2024, 7:00 AM EDT - 6 months ago

Accolade Announces Results for Fiscal Second Quarter 2025

Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings

Oct 7, 2024, 8:01 AM EDT - 6 months ago

Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings

Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings

Oct 4, 2024, 4:19 AM EDT - 7 months ago

Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Sep 18, 2024, 8:00 AM EDT - 7 months ago

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 8:00 AM EDT - 8 months ago

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Aug 22, 2024, 10:03 AM EDT - 8 months ago

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 7, 2024, 8:00 AM EDT - 9 months ago

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

The Schall Law Firm Encourages Accolade Inc Investors To Join The Alleged Securities Fraud Probe

Jul 30, 2024, 9:00 AM EDT - 9 months ago

The Schall Law Firm Encourages Accolade Inc Investors To Join The Alleged Securities Fraud Probe

The Schall Law Firm Urges Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe

Jul 29, 2024, 3:45 PM EDT - 9 months ago

The Schall Law Firm Urges Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe

The Schall Law Firm Encourages Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe

Jul 23, 2024, 6:00 PM EDT - 9 months ago

The Schall Law Firm Encourages Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe